Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma
Latest Information Update: 13 Mar 2024
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 06 Mar 2024 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.
- 06 Mar 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Apr 2025.
- 01 May 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2024.